How does beclomethasone/formoterol/glycopyrrolate spray (Trimbow) work?

Beclomethasone/formoterol/glycopyrrolate spray (Trimbow), as an innovative triple therapy drug, has demonstrated significant efficacy in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. Its unique combination of drugs - long-acting beta-2 receptor agonists, inhaled corticosteroids and long-acting muscarinic receptor antagonists - work together on the patient's respiratory tract to provide patients with more comprehensive and effective disease control.

In the field of COPD treatment, Trimbow’s two large-scale clinical studies have provided strong evidence for its efficacy. The two studies involved more than 4,000 patients whose symptoms had not been adequately controlled by previous treatment with a combination of two other COPD drugs. In the first 26-week study, Trimbow significantly increased patients' FEV1 (the maximum amount of air that can be exhaled in one second) by 261 milliliters from pre-drug baseline levels, compared with 1 milliliter and 145 milliliters for patients treated with only the two active ingredients in Trimbow (beclomethasone plus formoterol). This data clearly demonstrates the advantages of Trimbow in improving lung function in COPD patients.

In a second study,Trimbow further demonstrated its effectiveness in reducing exacerbations. Patients treated with Trimbow experienced 20% fewer exacerbations (symptom flares) per year compared with patients treated with tiotropium, a muscarinic receptor antagonist. It is worth noting that Trimbow and tiotropium bromide combined with beclomethasone and formoterol showed similar efficacy in reducing the number of acute exacerbations, which further consolidated Trimbow's position in the treatment of COPD.

In terms of asthma treatment,Trimbow also shows excellent results. A study involving more than 1,000 asthma patients showed that their disease was not adequately controlled by a combination of moderate-dose inhaled corticosteroids and a long-acting beta-2 agonist. After 26 weeks of treatment, Trimbow (moderate intensity) significantly improved patients' FEV1, increasing it by 185 ml from baseline, while the beclomethasone plus formoterol combination only improved it by 127 ml. Additionally, patients treated with Trimbow for up to one year experienced a 15% reduction in moderate and severe exacerbations per year, demonstrating Trimbow’s long-term efficacy in asthma treatment.

In another study of high-dose inhaled corticosteroids versus long-actingTrimbow (higher intensity) also showed significant advantages in studies of patients with asthma that was not adequately controlled despite beta-2 agonist combination therapy. It improved patients' FEV1 and significantly reduced the number of exacerbations per year in a subgroup of patients with persistent airflow limitation. Although there was no statistically significant difference in the annual incidence of moderate to severe exacerbations between the two groups, Trimbow had a beneficial effect on the incidence of severe exacerbations.

In short, beclomethasone/formoterol/glycopyrrolate spray (Trimbow) has demonstrated significant efficacy in the treatment of COPD and asthma. It provides patients with a more comprehensive and effective disease control program by improving their lung function and reducing the number of exacerbations and acute exacerbations. As more clinical research is conducted and deepened, it is believed that Trimbow will become a treatment option for more COPD and asthma patients in the future.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/trimbow